查看文章

Cancer is one of the major public health problems across the globe. The adverse effects and the evolving drug resistance to classical chemotherapeutics is a challenge for cancer therapy. A promising alternative to existing cancer therapy is the use of natural products or their derivatives as antitumor agents. Microorganisms, in particular actinobacteria, hold a prominent position in drug discovery programs since they produce a wide array of bioactive secondary metabolites with unparalleled chemical diversity. Actinobacteria are known to produce wide variety of clinically useful antitumor drugs such as Bleomycin, actinomycin D, doxorubicin, mithramycin, mitomycins, daunomycin, azynomycin B, aclarubicin, neocarzinostatin, and pentostatin. Drug discovery prospects from untapped species of actinobacteria are gaining attention for their potential to answer the drug resistance problems in cancer therapy. Extensive …